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Cancer is the first cause of death in China. Approxi-
mately 1.6 million people died of cancer and more than
2.2 millions of new cases were diagnosed each year. In
order to reveal the puzzle of genomic alterations and
biology of human cancers, the new-generation sequen-
cing technology has been set up and started to carry out
large-scale cancer genome study in China. The Chinese
Cancer Genome Consortium (CCGC) was organized in
August 2008 to launch and coordinate a number of
research projects as a publicly-funded network with over
30 university hospitals and research institutions to share
a common goal and platform.
The CCGC has done a serial of activities including orga-
nization of clinical research teams and working groups,
the selection of cancer types and define of research strate-
gies, the technical and bioethical issues for bio-specimen
collecting and quality control, which shall be collected
using a Standard Operating Procedure (SOP) provided by
the CCGC Project Secretary Office following International
Cancer Genome Consortium (ICGC). We have proposed
the missions and working plan for coming 5 years.
The CCGC has announced approximately 15 types of
common cancers in China to be initiated, including gas-
tric, hepatocellular, esophageal, nasopharyngeal, colorectal,
bladder, lung, thyroid, breast, renal, ovary, pancreatic
cancer, leukemia and glioblastoma. Furthermore, we will
focus to optimize the biospecimen collection network and
running system for pathological and molecular quality
control to support CCGC projects to be healthy growth.
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